Clinical Trials in San Antonio

Showing 4061-4080 of 14,161 trials

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

NCT01906385

This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.

Glioma

Plus Therapeutics55 participantsStarted Jun 2015

Manhasset, New York, United States • Dallas, Texas, United States • San Antonio, Texas, United States

RECRUITINGPhase 2< 1 mile

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

MelanomaHead and Neck Squamous Cell CarcinomaColo-rectal Cancer

Vyriad, Inc.87 participantsStarted Apr 2020

Phoenix, Arizona, United States • Durate, California, United States • Los Angeles, California, United States +24 more locations

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Find Trials by Condition in San Antonio

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Oral Administration of STC-15 in Subjects With Advanced Malignancies

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Efficacy of Emotionally Focused Therapy Among Spanish Speaking Couples

In-Utero Endoscopic Correction of Spina Bifida

Kids FACE FEARS Comparative Effectiveness Research